We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
101
Harrow
HROW
$1.45B
$2.56M 0.19%
+458,607
New +$2.75M
MBIO icon
102
Mustang Bio
MBIO
$4.32M
$2.54M 0.18%
1,075
+600
+126% +$1.48M
NKTR icon
103
CALL
Nektar Therapeutics
NKTR
$2.39B
$2.49M 0.18%
10,000
– –
XENE icon
104
Xenon Pharmaceuticals
XENE
$6.06B
$2.47M 0.18%
223,173
-75,000
-25% -$882K
ACHV icon
105
Achieve Life Sciences
ACHV
$659M
$2.38M 0.17%
284,151
+101,224
+55% +$928K
CASI
106
DELISTED
CASI Pharmaceuticals
CASI
$2.36M 0.17%
153,991
+50,000
+48% +$942K
CLVS
107
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$2.33M 0.17%
400,000
-76,900
-16% -$460K
ACAD icon
108
Acadia Pharmaceuticals
ACAD
$4.43B
$2.31M 0.17%
56,008
+10,000
+22% +$432K
BLUE
109
DELISTED
bluebird bio
BLUE
$2.17M 0.16%
3,110
-4,986
-62% -$3.89M
PSTX
110
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.02M 0.15%
+228,000
New +$2.59M
FATE icon
111
CALL
Fate Therapeutics
FATE
$286M
$2M 0.15%
50,100
– –
FATE icon
112
PUT
Fate Therapeutics
FATE
$286M
$2M 0.15%
50,100
– –
QNCX icon
113
Quince Therapeutics
QNCX
$22.9M
$2M 0.14%
+200
New +$1.82M
OTIC
114
DELISTED
Otonomy, Inc.
OTIC
$1.76M 0.13%
434,786
-632,485
-59% -$2.38M
NXTC icon
115
NextCure
NXTC
$16.8M
$1.76M 0.13%
+16,667
New +$2.05M
DMAC icon
116
DiaMedica Therapeutics
DMAC
$342M
$1.76M 0.13%
+415,000
New +$2.2M
VSTM icon
117
Verastem
VSTM
$510M
$1.71M 0.12%
117,777
-41,667
-26% -$690K
APTX
118
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.68M 0.12%
495,490
-95,510
-16% -$366K
RIGL icon
119
Rigel Pharmaceuticals
RIGL
$681M
$1.67M 0.12%
69,553
-98,500
-59% -$2.42M
TECX
120
Tectonic Therapeutic
TECX
$529M
$1.63M 0.12%
+10,417
New +$2.1M
SLDB icon
121
Solid Biosciences
SLDB
$794M
$1.6M 0.12%
52,534
– –
ICAD
122
DELISTED
iCAD Inc
ICAD
$1.6M 0.12%
181,337
-130,931
-42% -$1.29M
ALT icon
123
Altimmune
ALT
$552M
$1.5M 0.11%
113,768
-51,232
-31% -$1.02M
AUPH icon
124
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.47M 0.11%
+100,000
New +$1.45M
IMMU
125
CALL
DELISTED
Immunomedics Inc
IMMU
$1.37M 0.1%
16,100
– –
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.